Simpson Thacher is representing EQT Partners in connection with its announced acquisition of Certara, the leading provider of technology driven decision support solutions for drug development, from Arsenal Capital Partners for $850 million. This is EQT’s second major U.S. healthcare acquisition – the first being the Press Ganey acquisition in August 2016, in which Simpson Thacher also advised EQT.
EQT is a leading European private equity group with approximately £30 billion in raised capital. EQT has portfolio companies in Europe, Asia and the U.S. with total sales of more than £15 billion and circa 100,000 employees.
The Simpson Thacher team includes Robert Langdon, Michael Holick, Fred De Albuquerque, Mark Myott, Matthew Kemp, Willimina Bromer and Ashleigh Taylor (M&A); Jennifer Hobbs, Eli Isak and Deepa Thimmapaya (Banking & Credit); David Rubinsky, Patricia Adams and Michael Cook (Executive Comp/Employee Benefits); Jonathan Goldstein and Jasmine Hay (Tax); Jason Glover and Vasanth Padaki (Private Funds); Sara Razi, Ellen Frye, Kelly Karapetyan and Muran Zhu (Antitrust); Jeff Ostrow and Amber Harezlak (IP); Timothy Gallagher (Real Estate); and Steven DeLott (Insurance). Associates Scott Winston and Chajin Wu and Summer Associate Nick Qiu also provided valuable assistance.